Surface Ocean Biogeochemistry Regulates the Impact of Anthropogenic Aerosol Fe Deposition on the Cycling of Iron and Iron Isotopes in the North Pacific.

Distinctively-light isotopic signatures associated with Fe released from anthropogenic activity have been used to trace basin-scale impacts. However, this approach is complicated by the way Fe cycle processes modulate oceanic dissolved Fe (dFe) signatures (δ56Fediss) post deposition. Here we include dust, wildfire, and anthropogenic aerosol Fe deposition in a global ocean biogeochemical model with active Fe isotope cycling, to quantify how anthropogenic Fe impacts surface ocean dFe and δ56Fediss. Using the North Pacific as a natural laboratory, the response of dFe, δ56Fediss, and primary productivity are spatially and seasonally variable and do not simply follow the footprint of atmospheric deposition. Instead, the effect of anthropogenic Fe is regulated by the biogeochemical regime, specifically the degree of Fe limitation and rates of primary production. Overall, we find that while δ56Fediss does trace anthropogenic input, the response is muted by fractionation during phytoplankton uptake, but amplified by other isotopically-light Fe sources.

Constraints on the Cycling of Iron Isotopes From a Global Ocean Model.

Although iron (Fe) is a key regulator of primary production over much of the ocean, many components of the marine iron cycle are poorly constrained, which undermines our understanding of climate change impacts. In recent years, a growing number of studies (often part of GEOTRACES) have used Fe isotopic signatures (δ56Fe) to disentangle different aspects of the marine Fe cycle. Characteristic δ56Fe endmembers of external sources and assumed isotopic fractionation during biological Fe uptake or recycling have been used to estimate relative source contributions and investigate internal transformations, respectively. However, different external sources and fractionation processes often overlap and act simultaneously, complicating the interpretation of oceanic Fe isotope observations. Here we investigate the driving forces behind the marine dissolved Fe isotopic signature (δ56Fediss) distribution by incorporating Fe isotopes into the global ocean biogeochemical model PISCES. We find that distinct external source endmembers acting alongside fractionation during organic complexation and phytoplankton uptake are required to reproduce δ56Fediss observations along GEOTRACES transects. δ56Fediss distributions through the water column result from regional imbalances of remineralization and abiotic removal processes. They modify δ56Fediss directly and transfer surface ocean signals to the interior with opposing effects. Although attributing crustal compositions to sedimentary Fe sources in regions with low organic carbon fluxes improves our isotope model, δ56Fediss signals from hydrothermal or sediment sources cannot be reproduced accurately by simply adjusting δ56Fe endmember values. This highlights that additional processes must govern the exchange and/or speciation of Fe supplied by these sources to the ocean.

Constraints on soluble aerosol iron flux to the Southern Ocean at the Last Glacial Maximum.

Relief of iron (Fe) limitation in the Southern Ocean during ice ages, with potentially increased carbon storage in the ocean, has been invoked as one driver of glacial-interglacial atmospheric CO2 cycles. Ice and marine sediment records demonstrate that atmospheric dust supply to the oceans increased by up to an order of magnitude during glacial intervals. However, poor constraints on soluble atmospheric Fe fluxes to the oceans limit assessment of the role of Fe in glacial-interglacial change. Here, using novel techniques, we present estimates of water- and seawater-soluble Fe solubility in Last Glacial Maximum (LGM) atmospheric dust from the European Project for Ice Coring in Antarctica (EPICA) Dome C and Berkner Island ice cores. Fe solubility was very variable (1-42%) during the interval, and frequently higher than typically assumed by models. Soluble aerosol Fe fluxes to Dome C at the LGM (0.01-0.84 mg m(-2) per year) suggest that soluble Fe deposition to the Southern Ocean would have been ≥10 × modern deposition, rivalling upwelling supply.

Cloning of a phospholipase A2-activating protein.

Recently we have described the isolation and biochemical characterization of a phospholipase A2-activating protein (PLAP). We have cloned this protein and found it to be expressed as a 2.5-kilobase mRNA. The steady-state levels of PLAP mRNA are induced in smooth muscle and endothelial cells following treatment with leukotriene D4. The increased message levels coincide with increased amounts of PLAP. Synthetic antisense DNA was used to block the synthesis of PLAP and this treatment effectively blocked the activation of phospholipase A2 and the increased generation of prostanoids in smooth muscle and endothelial cells treated with leukotriene D4.

Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin.

Antibodies prepared against the phospholipase A2 stimulatory peptide melittin were used to identify and isolate a novel mammalian protein with similar functional and antigenic properties. The mammalian protein of Mr 28,000 was isolated from cell sonicates by high performance immunoaffinity chromatography and size exclusion chromatography. This stimulatory protein was stable for several months when frozen at -70 degrees C. The purified protein selectively stimulated phospholipase A2 when phosphatidylcholine was used as a substrate but had no effect on phospholipase A2 activity when phosphatidylethanolamine was used as a substrate. Furthermore, this protein had no effect on phospholipase C activity or on pancreatic or snake venom phospholipase A2. The stimulatory activity was unaffected by RNase or DNase treatment. However, boiling or trypsin digestion inactivated the phospholipase stimulatory activity. The mechanism of phospholipase A2 stimulation appeared to result from an increase in the apparent Vmax of the enzyme.

Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line.

We report the isolation of a platelet factor 4 (PF4) cDNA clone from a lambda gt11 expression cDNA library which was derived from a human erythroleukemic (HEL) cell line. The sequence of the DNA insert includes the 3'-untranslated region, the entire amino acid coding region for the mature PF4 protein, and a 5' region containing coding information for an additional 18 amino acids. In addition, supplemental genomic DNA sequencing shows that the full-length leader sequence is 30 amino acids long plus an initial methionine and codes for a hydrophobic signal-like sequence which is probably involved in transmembrane transport. A single species mRNA of approximately 800 nucleotides was detected on blots of HEL cell poly(A) + RNA using a labeled PF4 cDNA probe. The human PF4 leader sequence shares some DNA, but no amino acid, homology with the 15 amino acids at the N-terminus of mature bovine PF4, suggesting rapid divergence in this region of PF4 between these two species. Sequence comparison of the coding regions of mature PF4 and gamma IP-10, a protein induced in a variety of cells following treatment with gamma-interferon, shows a corrected divergence of 76%. The divergence of a common ancestor protein into PF4 and gamma IP-10 may have accompanied the development of sophisticated immune and coagulation systems in vertebrates. The availability of cDNA and genomic DNA information for these genes in other species will be useful in studying the evolution of the coagulation and immune systems.

Differential effects of aspirin and dexamethasone on phospholipase A2 and C activities and arachidonic acid release from endothelial cells in response to bradykinin and leukotriene D4.

The CPAE bovine endothelial cell line may be stimulated to produce eicosanoids. Leukotriene D4 increased the release of arachidonic acid primarily by activating phospholipase A2 while bradykinin activated the phospholipase C pathway. Cells pretreated with dexamethasone, a phospholipase A2 inhibitor, no longer responded to stimulation by LTD4 but did release arachidonic acid when treated with bradykinin. Aspirin blocked bradykinin-stimulated production of arachidonic acid but left the response to LTD4 unaffected. We conclude that these cells produce eicosanoids by activation of both PLA2 and PLC, and that the two different methods of arachidonic acid release can be distinguished by using the common anti-inflammatory drugs aspirin and dexamethasone.

Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells.

Incubation of the bovine endothelial cell line, CPAE, with leukotriene D4, leukotriene C4, bradykinin, or the calcium ionophore A23187 results in the release of arachidonic acid metabolites including 6-keto-prostaglandin F1 alpha, the stable metabolite of prostacyclin. Pretreatment of these cells with the pertussis toxin islet-activating protein (IAP) results in a dose-dependent inhibition of the release of arachidonic acid metabolites and prostacyclin in response to leukotriene D4 and leukotriene C4. In contrast, similar responses evoked by bradykinin or ionophore were not significantly altered by the IAP pretreatment of the cells. IAP in the presence of [32P]NAD specifically [32P]ADP-ribosylates a 41-kDa protein in membranes prepared from CPAE cells. Pretreatment of the intact cells with IAP resulted in a dose-dependent inhibition of subsequent 32P labeling of the toxin substrate in the membranes and correlates with the uncoupling of the leukotriene responses. These results suggest that the 41-kDa IAP substrate, presumably a guanine nucleotide regulatory protein, mediates the response of CPAE cells to leukotriene D4 and leukotriene C4, but not to bradykinin or the calcium ionophore.

Leukotriene D4 treatment of bovine aortic endothelial cells and murine smooth muscle cells in culture results in an increase in phospholipase A2 activity.

Leukotriene D4 stimulates prostanoid synthesis in smooth muscle and endothelial cells. Because phospholipases A2 and C have been proposed to regulate prostanoid synthesis, we examined the effect of leukotriene D4 on these activities. Leukotriene D4 treatment resulted in a dose-dependent, stereospecific increase in phospholipase A2 activity with phosphatidylcholine as a substrate. The induction of phospholipase A2 activity occurred just prior to the appearance of prostanoids in the media. Protein and RNA synthesis were required for the increase in phospholipase A2 activity, and the increase in activity resulted from an increase in the apparent Vmax of the phospholipase A2 enzyme. Phospholipase C activity using various substrates was unchanged. We conclude that the increase in prostanoid synthesis observed after leukotriene D4 treatment is a result of an increase in a phospholipase A2 activity.